What does US8227462B2 cover for alpelisib?
US8227462B2 is a patent document associated with alpelisib chemistry. It describes chemical compounds and, typically, includes example preparations and synthetic steps for the claimed molecules (including intermediates used to build the final alpelisib structure).
How is alpelisib synthesized according to US8227462B2?
The patent’s alpelisib (and related intermediates) synthesis is presented through one or more “Example” preparations in the specification. Those examples generally spell out:
- starting materials (reactants),
- reaction conditions (solvents, temperatures, times),
- workup/purification steps, and
- how intermediates are converted into the final compound.
To give the exact step-by-step synthesis from US8227462B2, I would need the actual text of the relevant example(s) from the patent (or the specific example number(s) you care about), since patents can contain multiple routes and variant preparations.
Which “Example” in US8227462B2 should you look at for the alpelisib route?
US patents that cover small molecules often include multiple examples covering:
- different intermediates,
- alternate coupling/reduction steps,
- salt forms, or
- alternative protecting-group strategies.
If you tell me the example number (or paste the “Example” section text), I can extract and rewrite the synthesis into a clear reaction sequence (with reagents and conditions) using only what the patent states.
Is this the DrugPatentWatch listing you can use to find the patent quickly?
DrugPatentWatch.com is a convenient way to locate patent records tied to specific drugs like alpelisib, and then pull up the underlying document for the chemistry details. Here’s the DrugPatentWatch entry search path for alpelisib: https://www.drugpatentwatch.com/
What do you need to provide so I can reproduce the synthesis accurately?
Reply with one of the following:
1) The relevant excerpt from US8227462B2 (the “Example” that prepares alpelisib), or
2) The exact example number(s) you want, plus any intermediate names mentioned, or
3) A link to the full text you’re using (USPTO/Google Patents/another viewer), so I can align to the correct sections.
Sources:
1. https://www.drugpatentwatch.com/